Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
ALEMBIC | IPCA LABS | ALEMBIC/ IPCA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 57.8 | 26.5 | 218.1% | View Chart |
P/BV | x | 5.0 | 8.3 | 60.3% | View Chart |
Dividend Yield | % | 0.2 | 0.1 | 139.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-18 |
IPCA LABS Mar-19 |
ALEMBIC/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 72 | 1,042 | 6.9% | |
Low | Rs | 34 | 590 | 5.7% | |
Sales per share (Unadj.) | Rs | 4.7 | 298.6 | 1.6% | |
Earnings per share (Unadj.) | Rs | 6.1 | 35.0 | 17.4% | |
Cash flow per share (Unadj.) | Rs | 6.2 | 49.4 | 12.6% | |
Dividends per share (Unadj.) | Rs | 0.20 | 3.00 | 6.7% | |
Dividend yield (eoy) | % | 0.4 | 0.4 | 102.7% | |
Book value per share (Unadj.) | Rs | 40.7 | 247.1 | 16.5% | |
Shares outstanding (eoy) | m | 267.03 | 126.35 | 211.3% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 11.3 | 2.7 | 412.2% | |
Avg P/E ratio | x | 8.7 | 23.3 | 37.2% | |
P/CF ratio (eoy) | x | 8.5 | 16.5 | 51.4% | |
Price / Book Value ratio | x | 1.3 | 3.3 | 39.4% | |
Dividend payout | % | 3.3 | 8.6 | 38.2% | |
Avg Mkt Cap | Rs m | 14,139 | 103,108 | 13.7% | |
No. of employees | `000 | NA | 13.4 | 0.0% | |
Total wages/salary | Rs m | 207 | 7,874 | 2.6% | |
Avg. sales/employee | Rs Th | NM | 2,807.0 | - | |
Avg. wages/employee | Rs Th | NM | 585.8 | - | |
Avg. net profit/employee | Rs Th | NM | 329.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,255 | 37,732 | 3.3% | |
Other income | Rs m | 370 | 577 | 64.2% | |
Total revenues | Rs m | 1,625 | 38,309 | 4.2% | |
Gross profit | Rs m | 111 | 6,901 | 1.6% | |
Depreciation | Rs m | 38 | 1,824 | 2.1% | |
Interest | Rs m | 2 | 189 | 0.9% | |
Profit before tax | Rs m | 442 | 5,465 | 8.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1,212 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 24 | 1,042 | 2.3% | |
Profit after tax | Rs m | 1,630 | 4,422 | 36.9% | |
Gross profit margin | % | 8.9 | 18.3 | 48.4% | |
Effective tax rate | % | 5.4 | 19.1 | 28.4% | |
Net profit margin | % | 129.8 | 11.7 | 1,107.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,867 | 23,778 | 7.9% | |
Current liabilities | Rs m | 591 | 10,975 | 5.4% | |
Net working cap to sales | % | 101.6 | 33.9 | 299.6% | |
Current ratio | x | 3.2 | 2.2 | 145.8% | |
Inventory Days | Days | 94 | 104 | 90.8% | |
Debtors Days | Days | 74 | 66 | 111.6% | |
Net fixed assets | Rs m | 1,791 | 20,368 | 8.8% | |
Share capital | Rs m | 534 | 253 | 211.4% | |
"Free" reserves | Rs m | 10,324 | 30,971 | 33.3% | |
Net worth | Rs m | 10,858 | 31,224 | 34.8% | |
Long term debt | Rs m | 41 | 1,409 | 2.9% | |
Total assets | Rs m | 11,591 | 45,507 | 25.5% | |
Interest coverage | x | 260.9 | 30.0 | 870.8% | |
Debt to equity ratio | x | 0 | 0 | 8.4% | |
Sales to assets ratio | x | 0.1 | 0.8 | 13.1% | |
Return on assets | % | 14.1 | 10.1 | 138.9% | |
Return on equity | % | 15.0 | 14.2 | 106.0% | |
Return on capital | % | 15.2 | 17.3 | 87.7% | |
Exports to sales | % | 1.5 | 45.9 | 3.4% | |
Imports to sales | % | 21.0 | 16.6 | 126.3% | |
Exports (fob) | Rs m | 19 | 17,308 | 0.1% | |
Imports (cif) | Rs m | 263 | 6,266 | 4.2% | |
Fx inflow | Rs m | 19 | 17,308 | 0.1% | |
Fx outflow | Rs m | 264 | 6,266 | 4.2% | |
Net fx | Rs m | -244 | 11,042 | -2.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 4,923 | 4.8% | |
From Investments | Rs m | -224 | -1,563 | 14.3% | |
From Financial Activity | Rs m | -27 | -1,832 | 1.5% | |
Net Cashflow | Rs m | -15 | 1,528 | -1.0% |
Indian Promoters | % | 64.0 | 45.9 | 139.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.2 | 11.4 | 1.8% | |
FIIs | % | 9.7 | 25.3 | 38.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 26.1 | 17.4 | 150.0% | |
Shareholders | 54,701 | 36,892 | 148.3% | ||
Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare ALEMBIC With: ALEMBIC PHARMA STRIDES PHARMA SCIENCE FDC ASTRAZENECA PHARMA BIOCON
Compare ALEMBIC With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.
For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More